Consultant Interventional Cardiologist and Revascularisation Group Chair at Royal Brompton Hospital, London. His clinical focus is on use of intravascular imaging in complex PCI , CTO and cardiogenic shock. His clinical research interests focus on optical coherence tomography, calcific coronary disease and percutaneous ventricular support. Dr Hill was global co-chief investigator for the DISRUPT CAD III study and has served as UK principal investigator for multiple interventional trials. He has served as a CTO and complex PCI proctor on a global basis and works closely with OPTIMA to focus on the development of OPTIMAL PCI. He is the founding co-director of the Complete Revascularisation (CoRe) meetings held every year in London.

After training in Scotland, Interventional Cardiology Fellowship at CUMC, and Clinical Research Fellowship at Harvard University, she was a Consultant Interventional Cardiologist at the Golden Jubilee National Hospital and Associate Professor of Cardiology at the University of Glasgow, prior to moving back to New York in 2022.

A consultant cardiologist at University Hospital Giessen, Giessen, Germany. Features in 4 videos on Wondr Medical. Holger Nef generally speaks on Coronary Interventions, Shockwave Lithotripsy (Coronary), Stable Coronary Artery Disease (CAD), and Calcified Lesions.

Prof. Flavio L. Ribichini is Full Professor of Cardiovascular Medicine and Director of the Division of Cardiovascular Medicine of the University of Verona, where he has served since 2006. Since 2022, he has been a chief of the cardio-thoracic department. Dedicated full time to Interventional Cardiology since 1993, he was Associate Professor of Cardiology and Director of the Catheterization Laboratory of the University Amedeo Avogadro in Novara, Italy from 2002 to 2006. He also worked as a full-time staff cardiologist at the Intensive Care Unit and the Catheterization Unit at Ospedale Santa Croce in Cuneo, Italy in the nineties. Prof. Ribichini obtained his medical degree in 1986 at the National University of Cordoba, Argentina, and then completed his fellowship in Internal Medicine in 1988. He obtained his board certification in Cardiology at the University of Torino, Italy in 1992. He had extensive training around the world in interventional cardiology, including at the University of Paris VII, Henry Mondor Hospital; Stanford University, California; and Mount Sinai Medical School, New York. In addition, he was a awarded a Research Fellowship of the ESC at the OLVZ Cardiovascular Centre, Aalst, Belgium. Prof. Ribichini is the Director of the School of Cardiovascular Medicine and the President of the PhD Department of the University of Verona. He is member of the Editorial Board of the European Heart Journal, member of the Executive Board of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), member ESC Guidelines Task Force, and of the of the scientific committee of the Euro-PCR and the TCT. He is Coordinator, Principle Investigator, and member of the steering committees of several clinical trials and has authored over 350 full publications on clinical and basic cardiovascular research in peer reviewed scientific journals available on PubMed with an H index: 42.

Prof Carlo Di Mario is Professor of Cardiology at the University of Florence and Director of the Structural 
Interventional Cardiology Division of the University Hospital Careggi, Florence, Italy. Previous posts included 15 years as 
Professor of Clinical Cardiology at Imperial College of Sciences,
 Medicine & Technology, London and Consultant Cardiologist at 
the Royal Brompton Hospital. He also practiced at the San 
Raffaele University Hospital, Milan, Italy. He trained in Cardiology at the 
University of Padova, Italy, but he soon moved for interventional training at the Thoraxcentre of Rotterdam, the Netherlands, where he also completed a PhD in Intracoronary Ultrasound Imaging and Doppler. Despite his teaching, research and administrative commitments, he maintains an active clinical involvement performing more than 100 PCI per year with special interest in the treatment of calcified lesions, chronic total occlusions, bifurcations, and diffuse disease. He is a regular TAVI operator and certified implanter for the Medtronic Evolut R and Edwards Sapien 3 transcatheter aortic valves. He participated in more than 260 MitraClip implantations in London and Florence and has recently started direct annuloplasty with the CardioBand. Professor Di Mario pioneered the use of intracoronary Doppler, pressure measurement, intravascular ultrasound, optical coherence tomography, and near infrared spectroscopy. He was PI of the OPTICUS trial, failing to demonstrate superiority of IVUS guided stenting, and of the Lipid Rich Plaque study, due to report at TCT 2018. He was Principal Investigator of the DESTINI trial, using Doppler CRF to identify lesions in need of stenting, and of the CARESS in AMI trial, a large multicentre trial showing that patients who receive fibrinolytic therapy for ST-elevation myocardial infarction benefit from early angioplasty. This trial and a subsequent meta-analysis have led to a change in the European Society of Cardiology and AHA/ACC Guidelines for treatment of STEMI patients. He cooperated with Dr Davies to the validation of iFR to assess lesion severity and discriminate the contribution of individual lesions, and with Dr Lyon in the intracoronary delivery of SERCA-2 genes via adenoviral vectors in the CUPID2 trial. He was the main recruiter of the DISRUPT-I-CAD study and is PI of the DISRUPT-II trial, both pioneering the use of coronary lithotripsy for calcified coronary lesions.